Navigation Links
GW Pharmaceuticals to Report Interim 2013 Results and Host Conference Call on 3 June, 2013
Date:5/14/2013

LONDON, May 14, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will be announcing interim financial results for the six months ended 31 March 2013 on Monday, 3 June 2013, prior to the UK stock market open. GW will also host a conference call the same day at 1:00 p.m. BST (8:00 a.m. EDT). GW is currently in a "quiet period" due to the Company's recent Initial Public Offering of American Depository Shares on the Nasdaq Capital Market exchange and has decided to hold its Interim results presentation after the expiration of this quiet period.

Conference call information will be provided in the interim financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.

About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 21 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has established a world leading position in the development of plant-derived cannabinoid therapeutics and has a deep pipeline of additional cannabinoid product candidates, including two distinct compounds, GWP42004 and GWP42003, in Phase 2 clinical development for Type 2 diabetes and ulcerative colitis, respectively, and at least two additional programs expected to enter Phase 1 and Phase 2 clinical trials in the next 12 months. For further information, please visit www.gwpharm.com.


'/>"/>
SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... PARK , Israel , December 7, 2016 ... today the signing of a memorandum of understanding with Korean company ... between the companies will assist in expediting Kadimastem,s entry into international ... innovative treatment for severe diseases in general and ALS and diabetes ... , , ...
(Date:12/7/2016)... , Dec. 7, 2016 Boehringer Ingelheim ... in patients with unresectable malignant pleural mesothelioma (MPM) ... The data, presented at the 17 th ... Vienna , showed nintedanib plus pemetrexed/cisplatin ... plus pemetrexed/cisplatin, with a significantly improved PFS (9.4 ...
(Date:12/7/2016)... , Dec. 7, 2016  Ionis Pharmaceuticals, Inc. (NASDAQ: ... will present a company overview at the BMO Capital Markets Prescriptions ... New York, NY . A live webcast of ... of the Ionis website.  The replay will be available within 48 ... ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... 2016 , ... It is vital for any lab to secure funding, and ... team at Beckman Coulter has designed Kaluza, templates with advanced analytical tools to streamline ... operate in a GLP (Good Laboratory Practice) fashion. , With features designed to simplify ...
(Date:12/7/2016)... ... ... came time to blow out his candles on his 14th birthday, Estefano Reano had only ... team at Joe DiMaggio Children’s Hospital surprised his family with a phone call that made ... , “He was playing at home, when we got the phone call telling us there ...
(Date:12/7/2016)... ... ... One of two inventors from Glen Burnie, Md., has a granddaughter who ... is why the co-inventor and I have designed a new and better way to ... of the patent-pending AV-AIR, a device that serves as an alternative to conventional methods ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... that its fully redesigned website, which launched October 17, 2016, features comprehensive information ... design and easy-to-navigate layout. Visitors and patients can discover the latest clinical dermatology ...
(Date:12/7/2016)... City, CA (PRWEB) , ... December 07, 2016 , ... ... during the holidays and winter seasons. One major study analyzing heart attacks among ... compared to August of a given year. We would all agree of course–no time ...
Breaking Medicine News(10 mins):